Apollomics Inc. Form 6-K Filing Summary

This filing contains unaudited condensed consolidated interim financial statements for the six months ended June 30, 2025, and management's discussion and analysis. Key financial highlights include revenue of $8,500,000 for the six months ended June 30, 2025, compared to no revenue for the same period in 2024. The company reported a net loss of $12,536,000 for the six months ended June 30, 2025, a decrease from a net loss of $35,206,000 for the same period in 2024. As of June 30, 2025, the company had cash and cash equivalents of $2,094,000 and net current liabilities of $343,000. The company has identified substantial doubt about its ability to continue as a going concern within one year due to insufficient liquidity and will require additional capital. The filing also details the company's operations, including a licensing agreement with LaunXP International Co., Ltd. for vebreltinib, and notes on share-based payments and financial instruments.